Engineering a Nano/Biointerface for Cell and Organ-Selective Drug Delivery

The field of nanomedicine has rapidly grown in the past decades. Although a few nanomedicines are available in the market for clinical use, it is still challenging to develop nanomedicine targeting tissues beyond the liver. It has been recognized that even though the nanoparticles are modified with targeting ligands, the formation of a protein corona on the surface of nanoparticles in the biological fluids results in limited progress in nano -particle-based drug delivery to specific cells or tissues. In this Perspective, we will discuss the role of surface properties in determining the formation of the protein corona and summarize the recent progress in engineering the nano/bio interface for protein-corona-mediated cell-and organ-selective drug delivery. Moreover, current challenges in the field and insights into designing new strategies for targeting drug delivery with a better understanding of the protein corona will be discussed.

Automated summary

The field of nanomedicine is growing rapidly, but there are still challenges in targeting tissues beyond the liver. The formation of a protein corona on the surface of nanoparticles in biological fluids affects their drug delivery efficiency. Engineering the nano/bio interface can enhance protein-corona-mediated cell and organ-selective drug delivery.